NCT01521325View on ClinicalTrials.gov

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
MesotheliomaPancreatic CancerOvarian CancerNon-small Cell Lung Cancer
Interventions
DRUG

Amatuximab

Subjects will receive one infusion of radiolabeled amatuximab.

Trial Locations (1)

20892'

National Cacner Institue, Bethesda

Sponsors

Lead Sponsor

Morphotek
All Listed Sponsors
lead

Morphotek

INDUSTRY